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Purpose or Objective: In order to evaluate the usefulness of 
high-dose-rate interstitial brachytherapy (HDR-ISBT) as 
monotherapy for locally limited mobile tongue cancer, we 
analyzed our clinical experience. 
 
Material and Methods: We investigated 29 locally limited 
mobile tongue cancer treated by HDR-ISBT as monotherapy at 
National Hospital Organization Osaka National Hospital 
between February 2001 and August 2012. The median age of 
the patients was 60 years (range: 34–84 years). All patients 
had histologically confirmed squamous cell carcinoma. 
According to the UICC classification of 2007, 3 T1, 18 T2 and 
8 T3 were classified, respectively. The median tumor 
thickness of the patients was 10 mm (range: 2–45 mm). Ten 
(34%) medically poor risk patients (more than 80 years of age 
or severe intercurrent disease) were included. One patient 
had previous irradiation history. All but one patients received 
54 Gy in 9 fractions. The other patient reduced his treatment 
doses (48 Gy in 8 fractions) because of previous irradiation 
history. We used three-dimensional planning for later 7 
patients and delivered the prescribed doses to CTV (clinical 
target volume). Gross tumor volume (GTV) was defined with 
metal markers positions, applicator positions, intraoral 
ultrasonography and CT image. The GTV was equal to the 
CTV. 
 
Results: The median follow-up time was 47 months (range; 
10-171 months). The median V100(CTV) were 100%prescribed 
dose (range; 99.6-100%) for 7 evaluable patients. The 4-year 
local control rates were 100%, 73% and 88% for T1, T2 and T3. 
The 4-year overall survival rates were 67%, 66% and 31% for 
T1, T2 and T3. The 4-year local control rates were 88%, 83% 
and 60% for tumor thickness of <10 mm (12 patients), 10-19 
mm (12 patients) and ≥20 mm (5 patients). The 4-year overall 
survival rates were 63%, 67% and 40% for tumor thickness of 
<10 mm, 10-19 mm and ≥20 mm. Four (14%) patients showed 
moderate to severe radiation ulcer.  
 
Conclusion: Our treatment result of HDR-ISBT as 
monotherapy showed good local control result although there 
were many medically poor risk patients. Overall survival rate 
was worse for patients who had T3 tumor or tumor thickness 
of ≥20 mm. 
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Purpose or Objective: To evaluate the efficacy and safety of 
interstitial permanent low dose rate 125I seeds implantation 
under ultrasound guidance for local recurrent tumor of head 
and neck. 
 
Material and Methods: A total of 70 patients (median age, 
60years; range, 4–94 years) with malignant mass in head and 
neck were retrospectivel -y studyed ( from Jan. 2004 to Oct. 
2014). 6 were lost to follow-up, and 64 met the inclusion 
criteria. 81 lesions in head and neck implanted 125I seeds 
were evaluated. And 54 of 81 lesions were diagnosed cervical 
lymph node recurrence and another 27 lesions were local 
recurrence of primary or residual after first management. All 
the patient underwent 125I seed implantation guided by 
ultrasonography (Color Doppler Ultrasound with high 
frequency probe and guiding stabilization devices, Alokaα-10, 
Figure 1) with adequate local anesthesia. Postoperative 
dosimetry was routinely performed by TPS (3D treatment 
planning system; Beijing Fei Tian Industries, Inc.) for all 
patients. The actuarial D90 of the implanted 125 I seeds 
ranged from 100Gy to 160Gy (median:130Gy). The activity of 
125 I seeds ranged from 0.3mCi to 0.8mCi (median: 0.69mCi). 
The total number of seeds implanted ranged from 3 to 89 
(median: 20). The follow-up period ranged from1 to103.5 
months (median: 14months).The survival and local control 
probabilities were calculated by the Kaplan-Meier method 
(SPSS 16.0). 
 
Results: Among all the 81 lesions, totally response rate was 
80.2% , 22 lesions had complete remission CR (27%) and 43 
had partial remission PR (53%) . The 1- ,3-and 5-year tumor 
control rates were all 75.2% , 73% and 69.1%respectively. The 
results of cervical lymph node recurrence shows better than 
the recurrence or residue of primary head and neck 
neoplasm, with the local control of 5 year was 72.7% and 
39.9% respectively. As of the date of follow-up, 22 of 64 
patients still alive , The 1- and 3-,5-year overall survival 
rates were 57.4% , 31%, 26.6% respectively, with a median 
survival of 20 months. Grade 4 side effects of skin ulceration 
was seen in 2 patient; grade 1 or 2 skin reactions were seen 
in 11 patients (17%) who had received external beam 
radiation therapy before. Other severe complications were 
not seen. 
 
 
 
Conclusion: Interstitial permanent implantation of 125 I 
seeds under ultrasound guidance is feasible, efficacious and 
safe for refractory head and neck metastasis or recurrence. 
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Purpose or Objective: A new methodology using magnetic 
resonance (MR) imaging for brachytherapy dose planning of 
esophageal cancer has been developed. The main objective 
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have been to determine an MR sequence capable of 
visualising the tumour and finding a suitable esophageal 
applicator that can be visualised on the MR images. 
 
Material and Methods: A total of six patients were included 
in this study. Each patient was scanned with one of two T2-
weighted sequences, inversion recovery fast spin echo (IR 
FSE) or fast recovery fast spin echo (FRFSE). To reduce the 
motion artefacts in the images, the scanning was only 
triggered when the diaphragm was at the end-exhale 
position. The imaging was performed on a 3.0 T MR (GE 
Healthcare). Dose planning on the obtained MR images was 
performed using two different methods 1) dose was 
prescribed at 10 mm from the applicator’s centre, which is 
the method currently used at Skåne University Hospital for 
treatment based on 2D images 2) dose planning was 
performed by manual optimisation, i.e. the dwell times were 
manually adjusted until adequate tumour coverage was 
reached. To our knowledge, an MR-safe esophageal 
applicator could not be found at the time of this study. 
Instead a modified duodenal tube was used. Different 
contrast agents were studied with the purpose to render the 
tube’s visibility on the MR images. 
 
Results: The esophageal tumour was successfully visualised 
and delineated on T2-weighted images with the FRFSE 
sequences, whereas the tumour in the MR images from the IR 
FSE sequences was difficult to visualise due to poor image 
quality. Furthermore, improved dose coverage to the tumour 
was observed when the dose planning was manually 
optimised to the tumour volume, where V100% to the tumour 
was increased from 70% to 95% and D90% was increased by 
34%. Moreover, the esophageal applicator (duodenal tube) 
was filled with a saline solution, which was successfully 
visualised on the MR images. 
 
Conclusion: Brachytherapy dose planning for esophageal 
cancer with MR imaging enhances tumour visibility and the 
ability to optimise the dose to the tumour volume and organs 
at risk. 
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Purpose or Objective; Papillon50 contact brachytherapy has 
been used for early rectal cancer treatment in the UK since 
1993. Currently there are four centres treating and a few 
more are in the process of implementation. The National 
Institute for Health and Care Excellence has issued guidance 
on safety and efficacy from a clinical perspective. However, 
there is currently no guidance on quality assurance (QA) 
testing. This review assessed any significant differences in 
machine QA practice between the current UK Papillon50 
users. This is the first step towards standardising QA tests, 
tolerances and procedures in order to ensure that the 
accuracy of this technique is maintained at a high level 
across the UK.  
 
Material and Methods: Each centre provided in-depth 
information regarding their QA programme. Details on 
machine-specific design characteristics were also taken into 
account. An inter-departmental comparison was made with 
regards to the QA tests performed, the frequency of each 
test, the accepted accuracy of the results with respect to the 
set baselines, the setup for each test and the equipment 
used.  
 
Results: Significant differences were seen between centres in 
the QA tests in terms of types of test, frequency and 
acceptable accuracy. A tolerance variation of 10% versus 2% 
in the beam quality check and a difference of 2 mm versus 
0.5 mm in the radiation field size check were observed. The 
manufacturer provides a calibration jig with which all four 
centres carry out radiation output measurements. However, 
each centre uses its own HVL jig design. There are significant 
design differences between these jigs with respect to the 
source-to-detector distance (SDD), the narrow beam 
geometry achieved and the backscatter conditions. All 
centres use the 1996 IPEMB CoP for the determination of 
absorbed dose for x-rays below 300 kV generating potential 
and its Addendum (2005) as a reference for the 
determination of the radiation output. However, the 
reference conditions stated in the CoP were generally not 
met due to the inherent design of the calibration jig used.  
 
Conclusion: Significant differences exist between centres in 
the level of accuracy and extent of the QA programme. The 
very-low energy and short SDD in the Papillon50 system result 
in a very rapid dose fall-off. Differences in the design of the 
HVL jig may play an important role in the definition of the 
beam quality in such conditions. An extension of the CoP 
Addendum may be needed to include the achievable 
Papillon50 measurement conditions. This review highlights 
the need to carry out an independent audit in order to assess 
whether the inter-departmental variations observed could 
result in differences in the treatment received by patients. 
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Purpose or Objective: To develop and assess the feasibility 
of an in-house developed fluorescent screen based system on 
dose distribution verification of HDR brachytherapy 
treatment delivery. 
 
Material and Methods: The QA system consisted of a solid 
water block with various thicknesses on top of a fluorescent 
screen (Kodak, Lanex regular screen) and a PMMA block 
below the screen. The fluorescent signal light was reflected 
by a mirror below the transparent PMMA to a CCD camera. 
The whole system was contained in a light tight box. Dose 
linearity was examined in a previous experiment. In 
measurement, an Ir-192 source was loaded to an applicator 
positioned on top of the solid water block. Single source dose 
distribution without entrance dose effect was first acquired 
to help obtain a universal light deconvolution kernel. It will 
then be used in subsequent image processing. Two source 
dwell positions were placed in each measurement with equal 
weighting. Source intervals were 5 mm and 10 mm. Four 
different measurement distances were selected, ranging from 
5 mm to 30 mm away from the applicator. Various dwell 
times ranging from 0.8s to 8s were assigned at different 
depth to produce the optimal light output. Captured images 
were then processed by applying a median-filter and the 
deconvolution kernel to remove radiation induced noise and 
deconvolute the acquired image, respectively. After the 
image processing, images were normalized and a region of 
interest (ROI) (16 cm²) was selected. Gamma index 
comparisons were performed between acquired dose 
distributions and the respective depth calculated by TPS 
(Elekta, Oncentra). Two profiles which cross the central line 
of the source dwell positions were obtained. 
 
Results: The system can obtain a dose distribution with 
resolution 0.257 mm per pixel. Gamma index comparisons, 
(3% dose difference/1 mm DTA) were performed on all 8 
conditions. Results were tabulated in Table 1. 
 
